FDA: Mifepristone review won't be done until March

The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the...

Summary aggregated from The Hill's public RSS feed. The full reporting belongs to The Hill — please read it on their site.